GASPAR, N., L.V. MARSHALL, D. BINNER, R. HEROLD, R. ROUSSEAU, P. BLANC, R. CAPDEVILLE, J. CARLEER, C. COPLAND, Y. KERLOEGUEN, K. NORGA, L. PACAUD, M.A. SEVAUX, C. SPADONI, Jaroslav ŠTĚRBA, F. LIGAS, T. TAUBE, M. UTTENREUTHER-FISCHER, S. CHIOATO, M.A. O'CONNELL, B. GEOERGER, J.Y. BLAY, J.C. SORIA, S. KAYE, B. WULFF, L. BRUGIERES, G. VASSAL and ADJ PEARSON. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. Annals of Oncology. OXFORD: Oxford University Press, 2018, vol. 29, No 3, p. 766-771. ISSN 0923-7534. Available from: https://dx.doi.org/10.1093/annonc/mdy002.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE
Authors GASPAR, N. (250 France, guarantor), L.V. MARSHALL (826 United Kingdom of Great Britain and Northern Ireland), D. BINNER (826 United Kingdom of Great Britain and Northern Ireland), R. HEROLD (826 United Kingdom of Great Britain and Northern Ireland), R. ROUSSEAU (840 United States of America), P. BLANC (250 France), R. CAPDEVILLE (756 Switzerland), J. CARLEER (56 Belgium), C. COPLAND (826 United Kingdom of Great Britain and Northern Ireland), Y. KERLOEGUEN (756 Switzerland), K. NORGA (56 Belgium), L. PACAUD (756 Switzerland), M.A. SEVAUX (250 France), C. SPADONI (826 United Kingdom of Great Britain and Northern Ireland), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), F. LIGAS (826 United Kingdom of Great Britain and Northern Ireland), T. TAUBE (276 Germany), M. UTTENREUTHER-FISCHER (276 Germany), S. CHIOATO (380 Italy), M.A. O'CONNELL (380 Italy), B. GEOERGER (250 France), J.Y. BLAY (250 France), J.C. SORIA (380 Italy), S. KAYE (826 United Kingdom of Great Britain and Northern Ireland), B. WULFF (276 Germany), L. BRUGIERES (380 Italy), G. VASSAL (250 France) and ADJ PEARSON (826 United Kingdom of Great Britain and Northern Ireland).
Edition Annals of Oncology, OXFORD, Oxford University Press, 2018, 0923-7534.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 14.196
RIV identification code RIV/00216224:14110/18:00108516
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1093/annonc/mdy002
UT WoS 000429455000036
Keywords in English PEDIATRIC-PATIENTS; HODGKINS-LYMPHOMA; SOLID TUMORS; YOUNG-ADULTS; ONCOLOGY; CHILDREN; PARTICIPATION; APPROPRIATE; TEENAGERS; RECURRENT
Tags 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 10:03.
Abstract
The impressive progress recently observed in adult cancers through the introduction of new drugs has not yet been translated to adolescents 12-17 years of age [defined according to the International Conference on Harmonization (ICH) E11]. The current drug development landscape separates adult and paediatric drug development (Table 1). Adolescents are grouped with children, leading to a mismatch with a lack of trials for adolescents with relapsed cancer and delayed access to new, effective drugs already available for adults.
Links
NV16-33209A, research and development projectName: Sekvenování nové generace a expresní profilování jako diagnostický podklad pro návrhy individualizovaných léčebných plánů pro děti se solidními nádory
NV16-34083A, research and development projectName: Receptorové tyrozinkinázy a navazující signální dráhy jako potenciální cíle léčby refrakterních solidních nádorů dětského věku
PrintDisplayed: 25/6/2024 05:04